Utilize este identificador para referenciar este registo: https://hdl.handle.net/1822/61777

Registo completo
Campo DCValorIdioma
dc.contributor.authorVieira, Raquelpor
dc.contributor.authorSouto, Selma B.por
dc.contributor.authorSánchez-López, Elenapor
dc.contributor.authorMachado, Ana Lópezpor
dc.contributor.authorSeverino, Patriciapor
dc.contributor.authorJose, Sajanpor
dc.contributor.authorSantini, Antonellopor
dc.contributor.authorFortuna, Anapor
dc.contributor.authorGarcía, Maria Luisapor
dc.contributor.authorSilva, Amelia M.por
dc.contributor.authorSouto, Eliana B.por
dc.date.accessioned2019-10-14T09:20:56Z-
dc.date.available2019-10-14T09:20:56Z-
dc.date.issued2019-10-10-
dc.identifier.citationVieira, Raquel; Souto, Selma B.; Sánchez-López, Elena; Machado, Ana López; Severino, Patricia; Jose, Sajan; Santini, Antonello; Fortuna, Ana; García, Maria Luisa; Silva, Amelia M.; Souto, Eliana, Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic SyndromeReview of Classical and New Compounds: Part-I. Pharmaceuticals, 12(4), 152, 2019por
dc.identifier.issn1424-8247por
dc.identifier.urihttps://hdl.handle.net/1822/61777-
dc.description.abstractDiabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed.por
dc.description.sponsorshipThis work was financially supported by the Portuguese Science and Technology Foundation (FCT/MCT) and from European Funds (PRODER/COMPETE) under the project reference M-ERANET/0004/2015-PAIRED and UID/AGR/04033/2019 (CITAB), co-financed by FEDER, under the Partnership Agreement PT2020, and also by the Institute of Nanoscience and Nanotechnology under the project ART(2018).por
dc.language.isoengpor
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)por
dc.relationUID/AGR/04033/2019por
dc.rightsopenAccesspor
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/por
dc.subjectdiabetes mellituspor
dc.subjectmetabolic syndromepor
dc.subjectglucose-lowering agentspor
dc.subjectsugar-lowering oilspor
dc.subjectphytotherapypor
dc.titleSugar-lowering drugs for type 2 diabetes mellitus and metabolic syndrome - review of classical and new compounds: Part-Ipor
dc.typearticle-
dc.peerreviewedyespor
dc.commentsCEB52077por
oaire.citationIssue4por
oaire.citationVolume12por
dc.date.updated2019-10-12T11:11:03Z-
dc.identifier.doi10.3390/ph12040152por
dc.description.publicationversioninfo:eu-repo/semantics/publishedVersion-
dc.subject.wosScience & Technologypor
sdum.journalPharmaceuticalspor
oaire.versionVoRpor
Aparece nas coleções:CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
document_52077_1.pdf925,88 kBAdobe PDFVer/Abrir

Este trabalho está licenciado sob uma Licença Creative Commons Creative Commons

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID